Truby, Lauren K. http://orcid.org/0000-0002-1874-0205
Regan, Jessica A.
Giamberardino, Stephanie N.
Ilkayeva, Olga
Bain, James
Newgard, Christopher B.
O’Connor, Christopher M.
Felker, G. Michael
Kraus, William E.
McGarrah, Robert W.
Shah, Svati H.
Clinical trials referenced in this document:
Documents that mention this clinical trial
The relationship between body mass index and cardiopulmonary exercise testing in chronic systolic heart failure
https://doi.org/10.1016/j.ahj.2009.07.016
Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial
https://doi.org/10.1016/j.ahj.2011.02.007
Myocardial perfusion, function, and dyssynchrony in patients with heart failure: Baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial
https://doi.org/10.1016/j.ahj.2009.07.009
Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure
https://doi.org/10.1016/j.ahj.2011.09.027
Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy
https://doi.org/10.1186/s12933-021-01353-z
Outcomes, health policy, and managed care: Relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure
https://doi.org/10.1016/j.ahj.2009.07.010
Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION): Design and rationale
https://doi.org/10.1016/j.ahj.2006.11.007
Relation Among Body Mass Index, Exercise Training, and Outcomes in Chronic Systolic Heart Failure
https://doi.org/10.1016/j.amjcard.2011.07.051
N-terminal pro–brain natriuretic peptide and exercise capacity in chronic heart failure: Data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study
https://doi.org/10.1016/j.ahj.2009.07.011
New York Heart Association functional class predicts exercise parameters in the current era
https://doi.org/10.1016/j.ahj.2009.07.017
Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction
https://doi.org/10.1016/j.ahj.2009.07.014
Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION)
https://doi.org/10.1016/j.ahj.2013.06.002
Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology—findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study
https://doi.org/10.1016/j.ahj.2011.09.017
The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure
https://doi.org/10.1016/j.ahj.2013.10.018
Baseline differences in the HF-ACTION trial by sex
https://doi.org/10.1016/j.ahj.2009.07.012
Effect of Peripheral Arterial Disease on Functional and Clinical Outcomes in Patients With Heart Failure (from HF-ACTION)
https://doi.org/10.1016/j.amjcard.2011.03.057
Funding for this research was provided by:
American Heart Association (16SFRN31800010)
Article History
Received: 17 May 2021
Accepted: 22 July 2021
First Online: 3 August 2021
Declarations
:
: The current study was approved by the Duke University Institutional Review Board.
: Not applicable.
: CMO receives grant or research support from Roche Diagnostics and Merck & Co. and consulting fees from Merck & Co., Bayer AG, Bristol-Myers Squibb, Windtree Therapeutics, Inc., and Arena Pharmaceuticals, Inc. GMF has received research grants from NHLBI, American Heart Association, Amgen, Merck, Bayer, Cytokinetics, and Roche Diagnostics; he has acted as a consultant to Novartis, Amgen, BMS, Cytokinetics, Medtronic, Cardionomic, Relypsa, V-Wave, Myokardia, Innolife, EBR Systems, Arena, Abbott, Sphingotec, Roche Diagnostics, Alnylam, LivaNova, Windtree Therapeutics, Rocket Pharma, and SC Pharma. The others authors have nothing to disclose.